Dopamine receptor D1, Dopamine receptor D2, and Dopamine receptor D4 (DRD1, DRD2, DRD4)

Dopamine receptors D1, D2, and D4 are G protein-coupled receptors (GPCRs) that mediate the physiological actions of the neurotransmitter dopamine in the central nervous system and peripheral tissues [1.1.1, 1.3.3]. They are categorized into two families: the D1-like family (including D1), which is typically Gs-coupled and stimulates adenylyl cyclase, and the D2-like family (including D2 and D4), which is Gi-coupled and inhibits adenylyl cyclase [1.2.1, 1.3.1]. These receptors play critical roles in regulating motor control, cognitive functions such as working memory and attention, and the brain's reward and motivation circuits [1.3.2, 1.3.5]. Dysregulation of these dopaminergic pathways is central to the pathophysiology of several major neuropsychiatric and neurodegenerative disorders, including schizophrenia, Parkinson's disease, and attention-deficit hyperactivity disorder (ADHD) [1.2.2, 1.3.4]. Pharmacological modulation of these receptors is a cornerstone of treatment; for instance, D2 receptor antagonism is the primary mechanism of most antipsychotic medications, while D1 and D2 receptor agonists are used to alleviate motor symptoms in Parkinson's disease [1.4.2, 1.4.4]. However, targeting these receptors often involves a trade-off between therapeutic efficacy and significant side effects, such as movement disorders or metabolic changes [1.1.2, 1.3.1].

Other names

DRD1DRD2DRD4D1 receptorD2 receptorD4 receptorD1-like receptorsD2-like receptors

D2 and D4 receptor antagonism for antipsychotic effects; D1, D2, and D4 receptor agonism for Parkinson's disease treatment; D2 receptor partial agonism for mood stabilization and psychosis; indirect agonism via dopamine reuptake inhibition or increased synthesis.